US 11,696,941 B2
Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same
Alan Remaley, Bethesda, MD (US); John T. Schiller, Kensington, MD (US); Marcelo Amar, Gaithersburg, MD (US); and Bryce Chackerian, Albuquerque, NM (US)
Assigned to THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, Bethesda, MA (US); and UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US)
Filed by THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US); and UNM Rainforest Innovations, Albuquerque, NM (US)
Filed on Jan. 22, 2021, as Appl. No. 17/155,549.
Application 17/155,549 is a continuation of application No. 16/250,514, filed on Jan. 17, 2019, granted, now 10,925,938.
Application 16/250,514 is a continuation of application No. 15/118,143, granted, now 10,279,019, issued on May 7, 2019, previously published as PCT/US2015/015408, filed on Feb. 11, 2015.
Claims priority of provisional application 61/938,450, filed on Feb. 11, 2014.
Prior Publication US 2021/0236608 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/005 (2006.01); A61P 9/10 (2006.01); C07K 9/00 (2006.01); C07K 11/00 (2006.01); A61K 39/00 (2006.01); A61K 38/10 (2006.01); C12N 9/64 (2006.01); A61K 47/69 (2017.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01)
CPC A61K 39/0005 (2013.01) [A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61K 47/6901 (2017.08); A61P 9/10 (2018.01); C12N 9/6454 (2013.01); C12Y 304/21061 (2013.01); A61K 2039/60 (2013.01); A61K 2039/627 (2013.01); C07K 9/00 (2013.01); C07K 11/00 (2013.01); C07K 14/47 (2013.01); C12N 2795/18123 (2013.01); C12N 2795/18134 (2013.01); C12N 2795/18141 (2013.01)] 14 Claims
 
1. A composition comprising:
a first antigenic proprotein convertase subtilisin-kexin type 9 (PCSK9) peptide linked to a bacteriophage virus-like particle (VLP) Qbeta immunogenic carrier, the first antigenic PCSK9 antigenic peptide comprising the amino acid sequence NVPEEDGTRFHRQASKC (SEQ ID NO:3); and
a second antigenic PCSK9 linked to a VLP Qbeta immunogenic carrier, the second antigenic PCSK9 peptide comprising:
the amino acid sequence SIPWNLERIIP (amino acids 150-160 of SEQ ID NO:1), or
the amino acid sequence SIPWNLERITP (amino acids 153-163 of SEQ ID NO:2);
with the proviso that the composition lacks a statin or includes a statin in an amount less than is effective to lower LDL to a desired extent when administered alone.